Application of cyclic dinucleotide (cGAMP) in anti-tumor field
US10092592B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2015 |
| Grant date | Oct 9, 2018 |
| Priority date | — |
| Expiry date | Apr 20, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/708
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention belongs to the field of medicine technology, particularly relating to an application of cyclic dinucleotide (cGAMP) in tumor treatment. Researches carried out in the present invention show that, cGAMP can inhibit growth of many types of tumor cells, with remarkable anti-tumor effect, thus, it can be used in preparation of anti-tumor drugs; and the prepared anti-tumor drugs have low toxicity and favorable effect. Proved by a subcutaneous tumor model in nude mice, cGAMP has a remarkable inhibition effect on tumors of human gastric carcinoma cell line MNK-45, human lung adenocarcinoma cell line A549, human colorectal carcinoma cell line Lovo, human hepatocellular carcinoma cell line SMMC-7721, human prostatic carcinoma cell line PC-3 and human pancreatic carcinoma cell SW1990, which are subcutaneously implanted in nude mice, and also proved by animal acute toxicity experiment. cGAMP has a relatively low acute toxicity, therefore and may be used for preparing anti-tumor drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.